The PD-L1 biomarker testing market share is witnessing remarkable expansion, thanks to its pivotal role in guiding cancer treatment decisions. By identifying patients likely to respond to immunotherapy, PD-L1 testing enables the adoption of personalized and highly effective treatment approaches.
With the increasing prominence of immunotherapy in oncology, the demand for PD-L1 testing is poised for steady growth. This surge is fueled by the continuous evolution of technology and the emergence of novel biomarkers, contributing to enhanced precision and efficacy in cancer care.
As healthcare endeavors towards more targeted and tailored treatment solutions, the PD-L1 biomarker testing market stands at the forefront of revolutionizing oncology management, promising brighter prospects for patients and clinicians alike.”
The PD-L1 biomarker testing market sale is expanding rapidly and is becoming increasingly important in the context of cancer diagnosis and treatment. PD-L1 biomarker testing is an essential component of immuno-oncology that guides the selection of immune checkpoint inhibitors as a treatment approach by determining the expression levels of PD-L1 in tumour cells. By the end of 2022, the market for PD-L1 biomarker testing is expected to be worth US$ 597.9 million. The market is expected to expand at a compound annual growth rate (CAGR) of 9.14% between 2023 and 2033, reaching a market size of over US$ 1.58 billion by that time.
Get Sample of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5897
Rising technological advancements in immunotherapy are propelling the adoption PD-L1 biomarker testing for non-small cell lung cancer as an effective means for therapeutic usage of PD-L1 proteins for benign lesions or tumor identification. Moreover, the unmet needs of cancer treatments are addressed by the growing availability of high-quality immunotherapy products worldwide. Lifestyle changes, such as physical inactivity, tobacco consumption and smoking, as well as unhealthy diet are prime factors responsible for the growing burden of cancerous indications in the current scenario.
The emergence of cancer immunotherapy has advanced the diagnostic approach to cancer detection and management, thus propelling the growth in the PD-L1 biomarker testing market. Key players operating in the market space are focusing on the development or extension of novel biologics using existing biologic resources for innovative product identification and provision of patented therapies.
Furthermore, the occurrence of adverse conditions such as organ failure and relapse into cancer through the process of chemotherapy is anticipated to fuel the adoption of PD-L1 biomarker testing among major healthcare facilities worldwide.
“Growing advancements in the field of oncology, along with accurate prediction insights offered by automated systems for biomarker testing will boost the sales of PD-L1 biomarker testing in the forthcoming years” says an Sabyasachi Ghosh.
Key Takeaways:
- Based on product, PD-L1 22C3 assay kits segment is projected to account for over 53% of the market share by 2032, with sales increasing at a 10.2% CAGR over the forecast period.
- In terms of indication, the NSCLS segment held 61.9% of the total market share in 2021, and the trend is expected to continue over the assessment period.
- By end user, sales in the cancer research institutes segment accounted for 43.2% of the total market share in 2021.
- North America is slated to be the largest leading region with a value share of over 61%, spearheaded by the U.S.
- Sales in the U.K. will increase at a 10% CAGR over the assessment period.
- China will emerge as a lucrative market, with demand growing at a 10.9% CAGR over the forecast period.
Competition Landscape
Leading players operating in the market are actively working in coherence with researchers to be able to acquire enhanced and innovative concepts to widen the therapeutic actions of the product. For instance:
- In May 2020, F. Hoffman-La Roche AG acquired Stratos Genomics to develop DNA-based sequencing for diagnostic use.
- In July 2020, Abcam plc. And Cancer Research UK partnered for the development and commercialization of novel antibodies to accelerate cancer research.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-5897
The study provides compelling insights on PD-L1 biomarker testing market segment based on product (PD-L1 22C3 assay kit, PD-L1 28-8 assay kit, PD-L1 SP142 assay kit and PD-L1 263 assay kit), indication (NSCLS, melanoma, renal cell carcinoma, gastrointestinal tract malignancy, haematological malignancies, ovarian cancer and others), end user (hospitals, diagnostic laboratories and cancer research institutes) across seven major regions.
Key Market Segments Covered In PD-L1 Biomarker Testing Industry Research
By Product:
- PD-L1 22C3 Assay Kit
- PD-L1 28-8 Assay Kit
- PD-L1 SP142 Assay Kit
- PD-L1 263 Assay Kit
By Indication:
- NSCLS
- Melanoma
- Renal Cell Carcinoma
- Gastrointestinal tract Malignancy
- Haematological Malignancies
- Ovarian Cancer
- Other
By End User:
- Hospitals
- Diagnostic Laboratories
- Cancer Research Institutes
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
